Aldurazyme
Scheie Syndrome
Genzyme, a Sanofi CompanyPhase 4 / ApprovedDormant
A
84/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 77/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Scheie Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
IDURONIDASE, .ALPHA.-L-(8-HISTIDINE) (HUMAN) Genzyme, a Sanofi Company | Phase 4 | BB |
Same molecule, other indications
Aldurazyme is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →